Safely reducing haemodialysis frequency during the COVID-19 pandemic

Michelle da Silva Lodge  
Salford Royal NHS Foundation Trust  
https://orcid.org/0000-0001-8371-3134

Thilini Abeygunaratne  
Salford Royal NHS Foundation Trust

Helen Alderson  
Salford Royal NHS Foundation Trust

Ibrahim Ali  
Salford Royal NHS Foundation Trust

Nina Brown  
Salford Royal NHS Foundation Trust

Constantina Chrysochou  
Salford Royal NHS Foundation Trust

Rosie Donne  
Salford Royal NHS Foundation Trust

Ibi Erekosima  
Salford Royal NHS Foundation Trust

Philip Evans  
Salford Royal NHS Foundation Trust

Emma Flanagan  
Salford Royal NHS Foundation Trust

Simon Gray  
Salford Royal NHS Foundation Trust

Darren Green  
Salford Royal NHS Foundation Trust

Janet Hegarty  
Salford Royal NHS Foundation Trust

Audrey Hyde  
Salford Royal NHS Foundation Trust

Philip A Kalra  
Salford Royal NHS Foundation Trust

Elizabeth Lamerton  
Salford Royal NHS Foundation Trust

David Lewis
Abstract

Background:

Patients undergoing haemodialysis (HD) are at higher risk of developing worse outcomes if they contract COVID-19. In our renal service we reduced HD frequency from thrice to twice-weekly in selected patients with the primary aim of reducing COVID 19 exposure and transmission between HD patients.

Methods:

Dialysis unit nephrologists identified 166 suitable patients (38.4% of our HD population) to temporarily convert to twice-weekly haemodialysis immediately prior to the peak of the COVID-19 pandemic in our area. Changes in pre-dialysis weight, systolic blood pressure (SBP) and biochemistry were recorded weekly throughout the 4-week project. Hyperkalaemic patients (serum potassium > 6.0mmol/L) were treated with a potassium binder, sodium bicarbonate and received responsive dietary advice.

Results:

There were 12 deaths (5 due to COVID-19) in the HD population, 6 of which were in the twice weekly HD group; no deaths were definitively associated with change of dialysis protocol. A further 19 patients were either hospitalised and/or developed COVID-19 and thus transferred back to thrice weekly dialysis as per protocol. 113 (68.1%) were still receiving twice-weekly HD by the end of the 4-week project. Indications for transfer back to thrice weekly were; fluid overload (19), persistent hyperkalaemia (4), patient request (4) and compliance (1). There were statistically significant increases in SBP and pre-dialysis potassium during the project.

Conclusions:

Short term conversion of a large but selected HD population to twice-weekly dialysis sessions was possible and safe. This approach could help mitigate COVID-19 transmission amongst dialysis patients in centres with similar organisational pressures.

Background

Severe Acute Respiratory Syndrome Coronavirus-2 has developed into a worldwide pandemic, with over 44 million documented cases and 1.1 million deaths worldwide. Medical comorbidities such as hypertension, diabetes mellitus, asthma, obesity and chronic kidney disease are reported as significant predictors of morbidity and mortality in COVID-19 patients [1,2].

The necessary frequency of haemodialysis (HD) is particularly pertinent at a time of a worldwide pandemic [3]. There is no randomised study demonstrating a beneficial effect of thrice weekly dialysis over twice weekly dialysis. HD patients are an “at-risk” group who have worse outcomes if they contract COVID-19 [4–6]. UK Renal Registry data up to 7th October 2020 has reported 21.1% mortality for in centre
HD patients who suffer COVID-19 [7]. Reducing frequency of dialysis for some patients who dialyse in-centre may minimise patient exposure to COVID-19, allow extra space between patients undergoing dialysis and help manage unprecedented HD staff sickness [8]. The counterpoint argument follows that dialysis reduction in patients with multimorbidity may increase overall morbidity, cardiovascular events and death, especially because of the longer interdialytic gap. This gap is notorious for being associated with higher risk of death and hospitalisation even in thrice weekly patients [9–11].

Dialysis reduction in selected patients was performed in our centre prior to the peak incidence of the COVID-19 pandemic in the North West of England, UK. The primary aim was to reduce COVID 19 exposure, transmission between patients and allow for social distancing whilst on the HD unit. It also permitted the formation of a ‘hot’ dialysis unit to cohort all suspected, proven cases and contacts for COVID-19, whereas non-exposed patients could be grouped into ‘cold’ satellite dialysis units. At the onset of this project we began collecting data in a structured way and this paper describes our methodology, outcomes and learning.

**Methods**

Our regional renal service has a catchment population of 1.55 million people and undertakes in centre haemodialysis for 432 patients in one main centre and 4 outlying satellite centres. The furthest distance between the main centre and satellite centres is 18 miles, which facilitated re-designation of patients without excessive travel times or major inconvenience. In centre HD patients were remotely reviewed (using electronic dialysis care records) by their own nephrologists to determine suitability for twice weekly dialysis (Figure 1). No definitive inclusion criteria were specified but only named patients dialysis consultants were asked to consider suitability for twice weekly based upon their review of interdialytic weight gain, pre-dialysis blood pressure and potassium, residual renal function, comorbidity and functional status. Patient concerns were addressed by the dialysis unit managers and by telephone review with their nephrologist to ensure shared decision making. All patients provided verbal consent to be included within this study. Exclusion criteria included; 1) already receiving twice weekly dialysis; 2) patient refusal 3) highly irregular attendance for dialysis 4) hospitalised on the 23rd March 2020. Patients were transferred to twice weekly dialysis at the beginning of the week commencing 23rd March 2020 and received telephone dietary and fluid advice regarding potential changes in fluid and food intake which may have been necessary. All twice weekly dialysis took place in the satellite centres which were maintained as ‘cold’ sites, whilst the main centre was designated the ‘hot site’ for dialysis of suspected and confirmed COVID-19 patients. The ‘hot’ site also grouped HD patients who were contacts within a COVID-19 household. Patients underwent structured active monitoring of their dialysis parameters between Monday 23rd March 2020 and Monday 20th April 2020. Target weight, pre-dialysis systolic blood pressure (SBP) and pre-dialysis potassium were taken from the first dialysis session of the week preceding conversion for comparative purposes. During week 1 (3/23/20 to 3/29/20) patients were dialysed on Monday and Friday if their usual days were Monday, Wednesday and Friday. Similarly, patients who dialysed on Tuesday, Thursday, Saturday were dialysed on Tuesday and Saturday. During
week 2, 3 and 4 patients were dialysed on Monday and Thursday, Tuesday and Friday or Wednesday and Saturday. Dialysis parameters were remotely reviewed at the end of each day for the first dialysis session of each week. Key safety indicators included pre-dialysis SBP, pre-dialysis weight gain, ultrafiltration rate (UFR) and pre-dialysis potassium (K+). Two nephrologists (JT + IE or IA or AH or PE) independently reviewed each patient’s dialysis data and agreed interventions. A pre-dialysis K+ of ≥ 6.5 mmol/L was the only absolute indication to convert back to thrice weekly dialysis. Increased surveillance of dialysis parameters were indicated if any of the following events occurred: SBP > 180 mmHg, UFR > 10 mL/kg/hr, pre-dialysis weight > 5% of target weight and > 3 litres ultrafiltration (UF) per session. Dietetic consultation and medical review of both dialysis sessions in that week were undertaken. Pre-dialysis potassium was monitored closely with the following management plan adopted:

| Pre-dialysis potassium (mmol/l) | Action |
|-------------------------------|--------|
| 5.7-6.0                       | Repeat pre-dialysis potassium at next dialysis session alongside dietetic telephone consultation |
| 6.1-6.4                       | Commence potassium binder (5g once a day of sodium zirconium cyclosilicate [12]), sodium bicarbonate 1g 3 times per day [13] and dietetic telephone consultation. Repeat pre-dialysis potassium at next dialysis session. If potassium > 6.0 at next session increase dose of binder by 5g OD to maximum 15g OD. |

Renal pharmacists and renal dietitians prescribed and managed the prescriptions, patient counselling and hyperkalaemia dietary advice. Dialysis prescriptions (including dialysate potassium) were not changed during this period. All patients were prescribed 4 hours of dialysis.

Demographic, comorbidity, biochemical and dialysis adequacy comparisons between patients who continued to receive thrice weekly dialysis and those transferred to twice weekly dialysis were performed. Diagnosis, medication and comorbidity data were taken from coded diagnoses available on hospital and primary care electronic medical records. Usual pre-dialysis blood pressures were calculated using the average of the last readings prior to 3/23/20. Urine output was not contemporaneously measured but patients who self-reported anuria (<100 mL per day) was recorded. Thirteen patients who commenced twice weekly dialysis after being identified later on during the course of this project were subsequently excluded from analysis in the thrice weekly group at baseline.

Patients who were hospitalised or admitted to the COVID-19 dialysis ‘hot unit’ were transferred to thrice weekly dialysis for the rest of the project. All hospitalisations were recorded after scrutinizing hub hospital (where the main centre is based) admission data and all referrals from surrounding district hospitals for the period 3/23/20 to 4/20/20. Patients were defined as COVID-19 positive after a positive nasal and/or throat COVID-19 PCR. Patients who were transferred back to thrice weekly dialysis completed 3 dialysis sessions in the following 7 days. Cause of death was obtained from death
certification and all fatal cases were discussed at a weekly multi-disciplinary mortality and morbidity meeting (including at least 5 nephrologists) to evaluate whether the reduction in dialysis frequency was contributory.

This is an observational report of a strategic and organisational restructuring of dialysis provision in our centre during the COVID 19 pandemic.

Statistical analysis

Data were analysed using means and standard deviations (parametric data) and medians and interquartile ranges (non-parametric data) where appropriate. Categorical data were compared using chi square test. Continuous data were compared using unpaired T test and Mann U Whitney. Significance of pre-dialysis SBP, potassium and weight changes were compared at each data point (after week1, after week 2 and after week 3) using Mann-Whitney U test. Data were analysed on an as-treated basis. Only patients participating in twice weekly dialysis at each time point were analysed.

Results

Baseline Characteristics

From a cohort of 432 in-centre dialysis patients 179 (41.4%) were identified as potentially suitable for and agreed to undergo twice weekly dialysis. This manuscript reports on the 166 (38.4%) patients who then commenced twice weekly dialysis on 3/23/20. Patients who were transferred to twice weekly dialysis were more likely to be older, with lower ultrafiltration volumes, greater urea reduction ratio (URR), shorter dialysis vintage and to have lower pre-dialysis phosphate and potassium levels. There was no significant difference in the frequency of primary renal diseases between the two groups and there were significantly less patients with heart failure transferred to twice weekly HD (table 1).

Longitudinal changes in dialysis parameters

Dialysis parameters of those patients who remained on a twice weekly dialysis regime demonstrated that pre-dialysis weight and interdialytic percentage increase in body weight remained unchanged (figure 2a and b). However, as the weeks progressed there was a significant increase in median SBP and potassium for those who remained on the twice weekly dialysis regime. These findings persisted after excluding patients who were known to be anuric (data not shown). The increase in SBP was apparent after 2 weeks of twice weekly dialysis (figure 2c) and the median SBP at the end of 3 weeks of twice weekly dialysis was 153 (140-172) mmHg compared with a median SBP at baseline of 145 (132-165) mmHg. The number of patients with a pre-dialysis SBP > 180 mmHg at baseline and after weeks 1,2 and 3 were 17, 18, 21 and 20, respectively.

There was a significant longitudinal increase in pre-dialysis potassium. This difference was apparent after 1 week of twice weekly dialysis (figure 2d). The median potassium at the end of 3 weeks in those patients able to continue twice weekly dialysis was 4.7 mmol/L (4.2-5.2) compared with 4.5 mmol/L (4.1-
4.9) at baseline. The number of patients with a pre-dialysis potassium above 6.0 mmol/L was 0, 8, 12 and 6 at baseline and after 1, 2 and after 3 weeks of twice weekly dialysis respectively.

**Technique Survival**

We determined this by including patients who died (6), patients automatically transferred back to thrice weekly dialysis because of hospitalisation (13) or suspected/confirmed COVID-19 infection (6) as “failing twice weekly dialysis”. There were 113 (68.1%) patients who were able to continue twice weekly dialysis for the whole 4 week period (figure 3). This resulted in 452 fewer dialysis sessions potentially minimising 452 potential exposures to COVID-19 both during dialysis and on transport to and from the units. There were 28 patients we electively transferred back to thrice weekly dialysis during the 4 weeks of the project. The indications for transfer back were fluid overload (n=19), hyperkalaemia despite use of binders (n=4), patient’s request (n=4) and compliance concerns (n=1). The characteristics of these 28 patients who we know “failed” twice weekly dialysis due to definite dialysis related reasons (rather than exposure or contraction of COVID-19 for example) are displayed in table 2.

**Other clinical outcomes**

The main outcomes for patients are displayed in table 3. There were 12 deaths in the entire HD population during these 4 weeks, of whom 6 had been transferred to twice weekly HD. No death was directly related to twice weekly dialysis (table 4). Two patients died from acute ischaemic events after 12 hours but within 48 hours of their last dialysis session, 1 patient died from COVID-19 pneumonia, whilst another died from suspected COVID-19 pneumonia. Two patients died at home >12 hours but <24 hrs after their last dialysis session; there was no suspicion of COVID-19. One was frail and elderly and the other was an unexpected sudden death that was referred to the coroner. Sudden cardiac death is a common cause of death for patients undergoing dialysis [22]. An association between dialysis reduction to this sudden death was not thought likely based upon dialysis parameters and laboratory results from the preceding dialysis session.

There were proportionately less patients who suffered COVID-19 in the twice weekly group but this difference was not statistically significant. There were no admissions with fluid overload in the twice weekly group during this 4-week project.

**Hyperkalaemia interventions**

There were 19 patients who received a prescription of sodium bicarbonate 1g thrice daily and sodium zirconium cyclosilicate alongside further dietetic advice. Two of these patients died (1 with normal potassium on admission and 1 with normal pre-dialysis potassium on the previous dialysis session (4.8 mmol/L)). 7/19 patients were subsequently transferred back to thrice weekly dialysis and 1 patient did not tolerate either medication. Nine patients continued to take the medications and dialyse twice weekly. Hyperkalaemia interventions reduced pre-dialysis potassium by 0.9 mmol/L (IQR 0.8-1.4); one patient’s potassium increased following intervention.
Discussion

This analysis found that the majority of patients who are deemed suitable to temporarily convert to twice weekly dialysis were able to safely dialyse twice weekly for at least 1 month during the COVID-19 pandemic, enabling safer grouping of patients to reduce potential viral exposure and transmission and ease service demands which may have been exacerbated by staff sickness. However, this was only possible with very close monitoring via dedicated clinician time and through the use of digital technology allowing remote monitoring of biochemistry and dialysis parameters. The necessity for close monitoring can be demonstrated for two reasons. Firstly, longitudinal assessment of dialysis parameters demonstrated statistically significant increases in pre-dialysis systolic blood pressures and pre-dialysis potassium in those patients who continued to receive twice weekly dialysis, although overall these parameters remained well within 'safe' limits. Secondly, it was also noted that the rate of patient transfer back to thrice weekly dialysis was constant throughout the project at around 3-4% per week.

Rising SBP despite no significant increase in pre-dialysis weight suggests that blood pressure changes were not necessarily related to increases in extracellular blood volume (ECV). This finding is not surprising given that more frequent dialysis has been shown to improve blood pressure control through various mechanisms. These include reduced ECV, increased sodium removal, reduced sympathetic tone and removal of vasoactive factors which may be driving hypertension [14–16]. There were similar numbers of patients with a pre-dialysis SBP > 180 mmHg before the project commenced compared with at the end of this twice weekly dialysis project (17 versus 20). A value of SBP > 180 mmHg as a trigger for closer dialysis parameter observation and possible conversion back to thrice weekly after the next dialysis session was based upon evidence that this value delineates an increased mortality risk in dialysis patients, although this evidence is conflicting [17].

There was little difference in the UF volumes in the twice weekly patients at baseline compared with those still maintaining on the twice weekly protocol at the end of the 4-week period (1.4 (1.0-2.0) litres per session compared with 1.5 (1.0-2.0) litres per session). However, this excludes the 19 (13.5%) patients who were transferred back to thrice weekly because of fluid-related issues. Table 3 demonstrates that patients with higher ultrafiltration at baseline were those who could not manage twice weekly dialysis for a four week period.

Due to reduced weekly dialysis time it is unsurprising that the median pre-dialysis potassium significantly increased every week. A pre dialysis potassium > 6.0 mmol/L has been suggested as a threshold whereby mortality risk substantially increases [18]. However only 6 patients had a pre-dialysis potassium above 6.0 mmol/L and 75% of the patients had a pre-dialysis potassium ≤ 5.4mmol/L at the end of this project. This was the same as in the thrice weekly population. Only 2 of the 6 patients with this degree of hyperkalaemia had previously had a pre-dialysis potassium above 6.0 mmol/L during the entire project. We had made no changes to dialysate potassium concentrations because recent evidence has suggested a higher mortality risk when patients are dialysed against a low potassium dialysate (1mEq/l), particularly those patients with a higher serum potassium [19]. The use of potassium binders, sodium
bicarbonate and responsive dietetic consultations mitigated against the need to increase dialysis session frequency in 9 patients. The role of potassium binders to reduce hyperkalaemia events and major adverse cardiovascular events in dialysis patients has not been researched in any randomised control study [12]. Potassium profiling was not used in this study but could be an option to mitigate hyperkalaemia in centres where this is an option [21].

There were no significant differences between hospitalisations, COVID-19 infections and deaths between the two groups although the twice weekly group were on average 6 years older than the thrice weekly group, perhaps representing a more at-risk group, although they had lower prevalence of heart failure. There was no definite evidence that any of the 6 deaths in the twice weekly dialysis group were caused by a reduction in dialysis frequency. There were no hospitalisations for fluid overload in the twice weekly group.

The analysis of this 4-week period of change in dialysis protocol is not intended to re-energise the debate over long-term dialysis frequency and dialysis dose but provides a potential methodology to appropriately and safely rationalise dialysis resources during a health service crisis such as the current pandemic. Although we are not recommending generalisation of our approach as health care management differs markedly throughout the world, it may have implications for other countries where dialysis resources are limited. Although we did not have definitive inclusion criteria, we have retrospectively surveyed the clinicians involved and together with the findings of this study we would suggest that short term switch to twice weekly dialysis is most appropriate for;

- Elderly patients
- Patients with lower ultrafiltration requirements/ higher residual renal function
- Patients whose pre-dialysis phosphate levels are within the normal range
- Patients whose pre-dialysis potassium levels are well within normal range
- Patients who share the decision to switch to twice weekly

We investigated complete conversion of patients to twice weekly dialysis. Future studies could investigate the impact of alternating twice to thrice weekly dialysis in selected groups of patients to
minimise COVID-19 exposure but maintain satisfactory dialysis parameters. At this stage, having passed the first peak of the COVID-19 pandemic in our geographical region, all our in-centre haemodialysis patients are now being individually reassessed for their suitability and preference for either home haemodialysis or peritoneal dialysis, the latter with particular relevance to patients with residual urine output currently treated with twice weekly haemodialysis. Patients who will not be suitable or do not wish to be transferred to home therapies and do not have significant formally quantified residual renal function will return to thrice weekly dialysis in a planned fashion over the next few weeks [20].

Conclusions

In conclusion, the COVID-19 pandemic is an international exceptional health crisis. This project demonstrates that reorganisation of dialysis provision for selected patients has the potential to protect patients and clinical staff. Patient selection and careful real-time monitoring can ensure that abrupt changes in dialysis provision are safe.

Limitations

This analysis did not fully evaluate dialysis adequacy which is reported to influence long term outcomes of HD as this project was primarily designed to overcome the short-term challenge of dialysis provision during a pandemic. It was not possible to perform contemporaneous measurements of residual renal function due to the short lead time of project set-up and there was considerable missing data regarding anuric status (47.6%). Regular measurement of residual renal function within the whole dialysis cohort would undoubtedly aid in decision making to determine suitability to convert to twice weekly haemodialysis at short notice. There was no measure of concordance with interventions (i.e. compliance with potassium binder medication) for hyperkalaemia although all but one patient’s potassium fell after its initiation. Whilst patient’s views were continually monitored during this period there were no quality of life or intradialytic health related quality of life symptoms recorded throughout the 4-week period.

List Of Abbreviations

ACEi– Angiotensin Converting Enzyme inhibitor, ADPKD – Autosomal Dominant Polycystic Kidney Disease, ARB - Angiotensin receptor blocker, BMI – Body Mass Index, COVID-19 – Coronavirus disease, CVA – Cerebrovascular event, HD – Haemodialysis, DBP – Diastolic Blood Pressure, ECV – Extracellular blood volume, IQR – Interquartile Range, K+ – Potassium, OD – Once Daily, SBP – Systolic Blood Pressure, UF – Ultrafiltration, UFR – Ultrafiltration Rate, URR – Urea Reduction Ratio.

Declarations

• Ethics approval and consent to participate
Online tools provided by the NHS Health Research Authority determined that research ethics committee review was not required in accordance with the UK Policy Framework for Health and Social Care Research. The study was performed in accordance with the declaration of Helsinki and approval for this study, including method of consent, was obtained from the Research and Innovation department of the Northern Care Alliance NHS Group (Ref: S19HRANA34). Patients provided verbal consent to be included in this project.

- **Consent to publish**

  Not applicable.

- **Availability of data and materials**

  All data generated or analysed during this study are included in this published article.

- **Competing Interests**

  Professor Kalra reports grants and personal fees from Vifor, personal fees from AstraZeneca, outside the submitted work. No other authors have anything else to declare.

- **Funding**

  Not applicable.

- **Author Contributions**

  The co-authorship list is large as it includes key health care staff that were involved in the organisation of and monitoring of this service change, and also all other consultant nephrologists in our department, in recognition of their great collaborative efforts during this exceptionally challenging period.

  All authors have read and approved the manuscript.

  Concept and proof reading: DP, PK, JT, RM, DN, JR, FR, RD, TC, TA, DL, NB, HA, DOD, EOR, PE, IA, IE, MR, GW, SS, LL, DG, RN, SG

  Data Collection: JT, IA, AH, PE, EF, IE

  Data Analysis: MDSL

  Manuscript: MDSL, PK, JT

- **Acknowledgements**
This piece of work could not have been performed without the understanding and flexibility of our renal patients. A great level of thanks must go to the renal dietetic team, pharmacy and administrative teams.

References

1. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern. Med. 2020;
2. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;
3. Scribner BH, Cole JJ, Ahmad S, Blagg CR. Why thrice weekly dialysis? Hemodial. Int. 2004;2:188–92.
4. Ikizler TA, Kliger AS. Minimizing the risk of COVID-19 among patients on dialysis. Nat. Rev. Nephrol. Nature Publishing Group; 2020. p. 1–3.
5. Scarpioni R, Manini A, Valsania T, De Amicis S, Albertazzi V, Melfa L, et al. Covid-19 and its impact on nephropathic patients: the experience at Ospedale “Guglielmo da Saliceto” in Piacenza. G. Ital. Nefrol. 2020;37.
6. Goicoechea. M, Sánchez Cámara LA, Macías N, Muñoz de Morales A, González Rojas Á, Bascuñana A, et al. COVID-19: Clinical course and outcomes of 36 maintenance hemodialysis patients from a single center in Spain. Kidney Int. Elsevier; 2020;
7. Renal Registry. COVID-19 surveillance report for renal centres in the UK - up to 6th May 2020. 2020;
8. Meyer TW, Hostetter TH, Watnick S. Twice-Weekly Hemodialysis Is an Option for Many Patients in Times of Dialysis Unit Stress. J. Am. Soc. Nephrol. American Society of Nephrology; 2020;
9. Mehrotra R. Counterpoint: Twice-Weekly Hemodialysis Should Be an Approach of Last Resort Even in Times of Dialysis Unit Stress. J. Am. Soc. Nephrol. American Society of Nephrology; 2020;
10. Fotheringham J, Fogarty DG, El Nahas M, Campbell MJ, Farrington K. The mortality and hospitalization rates associated with the long interdialytic gap in thrice-weekly hemodialysis patients. Kidney Int. 2015;88:569–75.
11. Foley RN, Gilbertson DT, Murray T, Collins AJ. Long interdialytic interval and mortality among patients receiving hemodialysis. N. Engl. J. Med. 2011;365:1099–107.
12. NICE. Sodium zirconium cyclosilicate for treating hyperkalaemia. Technol. Apprais. Guid. [TA599]. NICE; 2019;
13. Clinical and cost-effectiveness of oral sodium bicarbonate therapy for older patients with chronic kidney disease and low-grade acidosis (BiCARB): a pragmatic randomised, double-blind, placebo-controlled trial. BMC Med. Springer; 2020;18:1–16.
14. Charra B, Chazot C, Jean G, Hurot JM, Vanel T, Terrat JC, et al. Long 3 x 8 hr dialysis: a three-decade summary. J. Nephrol. 2003;16 :S64-S69.
15. Kotanko P, Garg AX, Depner T, Pierratos A, Chan CT, Levin NW, et al. Effects of frequent hemodialysis on blood pressure: Results from the randomized frequent hemodialysis network trials. Hemodial. Int.
16. Blankestijn PJ, Ligtenberg G. Volume-independent mechanisms of hypertension in hemodialysis patients: Clinical implications. Semin. Dial. Semin Dial; 2004. p. 265–9.

17. Chang TI. Systolic blood pressure and mortality in patients on hemodialysis. Curr. Hypertens. Rep. NIH Public Access; 2011;13:362–9.

18. Yusuf AA, Hu Y, Singh B, Menoyo JA, Wetmore JB. Serum Potassium Levels and Mortality in Hemodialysis Patients: A Retrospective Cohort Study. Am. J. Nephrol. S. Karger AG; 2016;44:179–86.

19. Ferrey A, You AS, Kovesdy CP, Nakata T, Veliz M, Nguyen D V., et al. Dialysate Potassium and Mortality in a Prospective Hemodialysis Cohort. Am. J. Nephrol. NIH Public Access; 2018;47:415.

20. Ashby D, Borman N, Burton J, Corbett R, Davenport A, Farrington K, et al. Renal Association Clinical Practice Guideline on Haemodialysis. BMC Nephrol. BioMed Central; 2019;20:379.

21. Agrawal D, Agrawal D, Tripathi N, Segal M. Potassim Profiling in Hemodialysis. Journal of Renal and Hepatic Disorders; 2018;2(2), 6-9.

22. Green D, Roberts P, New D, Kalra P. Sudden Cardiac Death in Hemodialysis Patients: An In-depth Review. American Journal of Kidney Diseases; 2011;57:921-929.

Tables

Table 1: Baseline clinical and laboratorial characteristics of HD patients
|                                | Twice weekly HD (n=166) | Thrice weekly HD (n=236) | p value  |
|--------------------------------|-------------------------|--------------------------|----------|
| Age (years)                    | 65.0 [54.8-74.3]        | 59.0 [49.0-71.0]         | <0.001   |
| Sex- Male (%)                  | 107 (64.5)              | 154 (65.3)               | 0.870    |
| Ethnicity - White British (%)  | 110 (66.3)              | 167 (70.8)               | 0.339    |
| Pre HD weight (Kg)             | 73.5 [62.0-85.3]        | 76.2 [64.2-91.4]         | 0.038    |
| BMI                            | 25.8 [22.9-29.4]        | 27.5 [23.3-31.6]         | 0.050    |
| Last URR (%)                   | 71.1 [65.4-75.5]        | 69.3 [63.1-74.4]         | 0.009    |
| Corrected Calcium (mmol/L)     | 2.36±0.18               | 2.34±0.17                | 0.283    |
| Phosphate (mmol/L)             | 1.56 [1.27-1.89]        | 1.68 [1.33-2.07]         | 0.023    |
| Parathyroid Hormone (pmol/L)   | 26.9 [12.5-56.8]        | 28.9 [13.2-51.9]         | 0.361    |
| Haemoglobin (g/L)              | 107±16.1                | 107±17.6                 | 0.873    |
| Potassium (mmol/L)             | 4.50 [4.00-5.20]        | 4.90 [3.20-5.50]         | <0.001   |
| Albumin (g/L)                  | 38.0 [34.1-41.0]        | 38.5 [35.0-41.0]         | 0.358    |
| Pre-HD average SBP             | 148±21.7                | 147±22.4                 | 0.617    |
| Pre-HD average DBP             | 74.0 [62.3-84.8]        | 77.5 [67.0-88.0]         | 0.082    |
| Post-HD average SBP            | 139 [126-154]           | 137 [121-156]            | 0.980    |
| Post-HD average DBP            | 72.0 [63.0-80.0]        | 71.5 [63.8-83.3]         | 0.584    |
| Average UF (L)                 | 1.40 [1.00-2.00]        | 2.00 [1.50-2.70]         | <0.001   |
| Anuric Status (n)              | 16                      | N/A                      |          |
| Dialysis Vintage (months)      | 21 (6.3-14.5)           | 29.5 (11.9-261)          | 0.013    |
| **Primary Renal Disease**      |                         |                          |          |
| Diabetic Nephropathy (%)       | 51 (30.7)               | 81 (34.3)                | 0.450    |
| Hypertensive/Renovascular disease (%) | 27 (16.3) | 30 (12.7) | 0.314    |
| Glomerulonephritis (%)         | 21 (12.7)               | 31 (13.1)                | 0.886    |
| ADPKD (%)                      | 15 (9.0)                | 13 (5.5)                 | 0.172    |
| Urological (%)                 | 13 (7.8)                | 24 (10.2)                | 0.425    |
| Pyelonephritis (%)             | 3 (1.8)                 | 11 (4.7)                 | 0.125    |
| ANCA-associated vasculitis (%) | 4 (2.4)                 | 5 (2.1)                  | 0.847    |
| Other (%)                      | 17 (10.2)               | 16 (6.8)                 | 0.214    |
| Comorbidity                              | Twice Weekly | Three Weekly | p-value |
|-----------------------------------------|--------------|--------------|---------|
| Unknown (%)                             | 15 (9.0)     | 25 (10.6)    | 0.610   |
| Ischaemic heart disease (%)             | 25 (15.1)    | 40 (17.0)    | 0.613   |
| Heart Failure (%)                       | 5 (3.0)      | 18 (7.6)     | **0.049**|
| CVA (%)                                 | 16 (9.7)     | 35 (14.8)    | 0.124   |
| Diabetes Mellitus (%)                   | 62 (37.4)    | 101 (42.8)   | 0.274   |
| ACEi (%)                                | 30 (18.1)    | 46 (19.5)    | 0.721   |
| ARB (%)                                 | 19 (11.5)    | 32 (13.6)    | 0.532   |

Results are expressed as mean±SD, median [IQR; interquartile range] or n (%). p-value calculated using unpaired T test for parametric data and Mann-Whitney U Test for non-parametric data. Categorical variables were analysed by Chi-square test. Abbreviations: BMI – Body Mass Index, HD – Haemodialysis, SBP – Systolic Blood Pressure, DBP – Diastolic Blood Pressure, URR – Urea Reduction Ratio, ADPKD – Autosomal Dominant Polycystic Kidney Disease, CVA – Cerebrovascular event, ACEi- Angiotensin converting enzyme inhibitor, ARB - Angiotensin receptor blocker. a=missing for 2 patients in twice weekly group. b=missing for 2 patients in twice weekly group and 4 patients in thrice weekly group. c=missing for 26 patients in twice weekly group and 38 patients in thrice weekly group. d=missing for 2 patients in twice weekly group. e=missing for 2 patients in twice weekly group. f=missing for 4 patients in twice weekly group and 78 patients in thrice weekly group. g=missing for 2 patients in twice weekly group h=missing for 2 patients in twice weekly group and 4 patients in thrice weekly group. i=missing for 1 patient in twice weekly group. j=Pre-HD average SBP data missing for 4 patients in twice weekly group and 4 patients in 3x week HD group. k=missing for 4 patients in twice weekly group and 4 patients in thrice weekly group. l=missing for 9 patients in twice weekly group and 10 patients in thrice weekly group. m=Post-HD average DBP data missing for 9 patients in twice weekly group and 10 patients in thrice weekly group. n=missing for 3 patients in twice weekly group. o=missing data 79 patients.
### Table 3: Baseline clinical and laboratorial characteristics for twice weekly patients

|                                | Twice weekly HD     | Thrice weekly HD   | p value |
|--------------------------------|---------------------|--------------------|---------|
| **URR (%)\(^a\)**             | 72.6 [66.4-77.2]    | 69.7 [62.7-74.8]   | **0.009**|
| **Corrected Calcium\(^b\) (mmol/L)** | 2.33 [2.20-2.42] | 2.33 [2.22-2.43] | 0.921   |
| **Phosphate\(^c\) (mmol/L)**   | 1.77 [1.44]         | 1.65 [1.33-2.09]   | 0.117   |
| **Potassium\(^d\) (mmol/L)**   | 4.80 [4.30-5.40]    | 4.90 [4.40-5.40]   | 0.329   |
| **UF per session (L)**         | 1.50 [1.00-2.03]    | 2.00 [1.40-2.63]   | **<0.001**|
| **COVID-19 positive (%)**      | 9 (5.4)             | 20 (8.5)           | 0.245   |
| **Hospitalisations (%)**       | 13 (7.8)            | 17 (7.2)           | 0.813   |
| **Deaths (%)**                 | 6 (3.6)             | 6 (2.5)            | 0.535   |

Results are expressed as median [IQR; interquartile range] or n (%). p-value calculated using Mann-Whitney U Test. Categorical variables were analysed by Chi-square test. Hospitalisation data includes patients who were hospitalised for COVID-19 and prior to death. \(^a\)=missing for 56 patients in twice weekly group and 126 patients in thrice weekly group. \(^b\)=missing for 9 patients in twice weekly group and 46 patients in thrice weekly group. \(^c\)=missing for 9 patients in twice weekly group and 46 patients in thrice weekly group. \(^d\)=missing for 32 patients in thrice weekly group. COVID-19, hospitalisations and deaths % calculated in relation to original number of patients n=166 / n=236.

Abbreviations: URR=urea reduction ratio, UF= ultrafiltration
|                                | Completed full trial (n=113) | Failed twice weekly dialysis (n=28) | p value |
|--------------------------------|-----------------------------|------------------------------------|---------|
| Age (years)                    | 63.1±14.2                   | 65.1±14.7                          | 0.5257  |
| Sex- Male (%)                  | 76 (67.3)                   | 12 (52.2)                          | 0.1686  |
| Ethnicity - White British (%)  | 78 (69.0)                   | 17 (73.9)                          | 0.6420  |
| Pre HD weight (Kg)             | 73.5 [62.0-83.2]            | 76.4 [71.6-86.6]                   | 0.1545  |
| BMI                            | 25.8 [22.7-28.8]            | 28.2 [24.5-32.9]                   | 0.0395  |
| Last URR (%)b                  | 70.6 [66.2-76.7]            | 72.5 [69.3-74.3]                   | 0.8383  |
| Corrected Calcium (mmol/L)     | 2.35±0.18                   | 2.36±0.18                          | 0.7784  |
| Phosphate (mmol/L)             | 1.55±0.44                   | 1.68±0.56                          | 0.2030  |
| Parathyroid Hormoneb (pmol/L)  | 28.3 [12.0-59.2]            | 25.7 [11.6-36.5]                   | 0.3732  |
| Haemoglobin (g/L)              | 108±15.5                    | 101±19.9                           | 0.0940  |
| Potassium (mmol/L)             | 4.52±0.77                   | 4.76±0.84                          | 0.1792  |
| Albumin (g/L)                  | 38.3±4.65                   | 35.0 [32.7-40.0]                   | 0.0557  |
| Pre-HD average SBP             | 148±21.3                    | 149±21.0                           | 0.8362  |
| Pre-HD average DBP             | 73.9±15.4                   | 74.8±13.1                          | 0.7889  |
| Post-HD average SBPc           | 138 [125-155]               | 134 [125-150]                      | 0.5987  |
| Post-HD average DBPd           | 71.0 [62.5-80.0]            | 72.0 [64.0-79.0]                   | 0.8243  |
| Average UF (L)                 | 1.30 [1.00-2.00]            | 2.20 [1.40-2.60]                   | 0.0007  |
| Dialysis Vintage (months)      | 19.2 (5.3-45.2)             | 20.7 (8.0-61.4)                    | 0.5270  |
| Primary Renal Disease          |                             |                                    |         |
| Diabetic Nephropathy (%)       | 35 (31.0)                   | 9 (39.1)                           | 0.4508  |
| Hypertensive/Renovascular disease (%) | 20 (17.7) | 4 (17.4)                           | 0.9727  |
| Glomerulonephritis (%)         | 13 (11.5)                   | 5 (21.7)                           | 0.1897  |
| ADPKD (%)                      | 11 (9.7)                    | 2 (8.7)                            | 0.8821  |
| Urological (%)                 | 9 (8.0)                     | 1 (4.3)                            | 0.5375  |
| Pyelonephritis (%)             | 2 (1.8)                     | 0 (0.0)                            | 0.5183  |
| ANCA-associated vasculitis (%) | 2 (1.8)                     | 0 (0.0)                            | 0.5183  |
| Other (%)                      | 11 (9.7)                    | 0 (0.0)                            | 0.1207  |
| Unknown (%)                    | 10 (8.8)                    | 2 (8.7)                            | 0.9877  |
| Comorbidity                    |                             |                                    |         |
| Ischaemic heart disease (%)    | 21 (18.6)                   | 2 (8.7)                            | 0.2502  |
| Heart Failure (%)              | 4 (3.5)                     | 1 (4.3)                            | 0.8523  |
| CVA (%)                        | 8 (7.1)                     | 6 (26.1)                           | 0.0065  |
| Diabetes Mellitus (%)          | 48 (42.5)                   | 10 (43.5)                          | 0.9298  |
| ACEi (%)                       | 24 (21.2)                   | 5 (21.7)                           | 0.9576  |
| ARB (%)                        | 18 (15.9)                   | 0 (0.0)                            | 0.0408  |

Results are expressed as mean±SD, median [IQR; interquartile range] or n (%). p-value calculated using unpaired T test for parametric data and Mann-Whitney U Test for non-parametric data. Categorical variables were analysed by Chi-square test. Abbreviations: BMI – Body Mass Index, HD – Haemodialysis, SBP – Systolic Blood Pressure, DBP – Diastolic Blood Pressure, URR – Urea Reduction Ratio, ADPKD – Autosomal Dominant Polycystic Kidney Disease, CVA – Cerebrovascular event, ACEi– Angiotensin converting enzyme inhibitor, ARB - Angiotensin receptor blocker.

a= missing for 13 patients in completed full twice weekly group and 5 patients in failed twice weekly group.
b=missing for 1 patient in failed twice weekly group. c=missing for 4 patients in completed full twice weekly group.
d=missing for 4 patients in completed full twice weekly group.
Table 4: Causes of death

| Cause                                      | Twice weekly HD | Thrice weekly HD |
|--------------------------------------------|-----------------|------------------|
| COVID Pneumonia                            | 1               | 4                |
| Cardiovascular Disease                      | 2               | 0                |
| Myeloma                                    | 0               | 1                |
| Natural Causes                             | 0               | 1                |
| Chronic Kidney Disease/End Stage Renal Disease | 2               | 0                |
| Uncertain (sudden death at home)*           | 1               | 0                |
| **Total**                                  | **6**           | **6**            |

Causes of death were taken from death certification records. All deaths were discussed in mortality and morbidity meetings to ensure there was no direct relationship between dialysis reduction and cause of death. *This patient has been referred for a coroner’s investigation (unrelated to twice weekly dialysis)

**Figures**
Figure 1

Consort diagram of patient participation
Figure 1

Consort diagram of patient participation
Figure 2

Changes in dialysis parameters in HD patients who remained on twice weekly dialysis. Statistical significance is shown by Mann-Whitney test: ns= not statistically significant, * p<0.05, **p<0.01, ***p<0.001 between twice and thrice weekly HD patients.
Figure 2

Changes in dialysis parameters in HD patients who remained on twice weekly dialysis. Statistical significance is shown by Mann-Whitney test: ns= not statistically significant, * p<0.05, **p<0.01, ***p<0.001 between twice and thrice weekly HD patients.
Figure 3

Technique survival curve in eligible population
Figure 3

Technique survival curve in eligible population